Aging Immune Cells May Betray the Hidden Face of Depression

Somewhere in your bloodstream, a type of white blood cell is quietly doing double duty. Monocytes are foot soldiers of the immune system, dispatched to sites of infection and inflammation with workaday efficiency. But these cells are also, it turns out, keeping a kind of biological diary, accumulating chemical modifications to their DNA that record how fast they are aging. And a new study suggests that diary may contain entries that have nothing to do with immunity. It could be tracking whether you are losing the capacity to feel joy.

Researchers at NYU and a consortium of institutions across the United States have found that accelerated aging in monocytes, measured through what are called epigenetic clocks, correlates with the cognitive and emotional symptoms of depression, particularly anhedonia and feelings of hopelessness. Not fatigue. Not poor appetite. The symptoms that are, in some ways, the hardest to pin down.

A Disorder That Wears Many Faces

Depression is notoriously difficult to diagnose objectively. There is no scan, no definitive blood panel, no reading you can take and say: yes, this person is depressed. Clinicians rely on questionnaires and clinical interview, which means the condition goes undetected at a rate that would alarm most people. It affects roughly one in five adults in the United States, yet its symptoms vary so wildly that two patients carrying the same diagnosis might barely overlap in what they experience. One arrives at a clinic reporting crushing fatigue and a changed appetite. Another describes a flattening of the world, a greyness, an inability to care about things that used to matter. Same label. Quite possibly different biology.

“Depression is not a one-size-fits-all disorder,” says Nicole Beaulieu Perez, an assistant professor at NYU Rory Meyers College of Nursing who led the study. “It can look really different from person to person, which is why it’s so important to consider varied presentations and not just a clinical label.”

The study, published in The Journals of Gerontology, Series A, drew on data from 440 women enrolled in the Women’s Interagency HIV Study, a long-running cohort. Of these participants, 261 were living with HIV and 179 were not. The choice of this population was deliberate. Women with HIV experience depression at particularly high rates, shaped by intersecting pressures: chronic inflammation, social stigma, economic precarity, and the psychological weight of managing a long-term illness. Their depression, when it goes unrecognized, makes it harder to adhere to antiretroviral therapy, which sets off a cascade that damages overall health. Finding an earlier, more objective signal matters enormously for this group.

Clocks Inside Cells

The researchers used two different epigenetic clocks to assess biological aging from blood samples. One, developed by Steve Horvath and widely used in aging research, integrates methylation patterns across many cell and tissue types. The other, MonoDNAmAge, is more targeted: it estimates the biological age of monocytes specifically. Both clocks produce a figure you can compare against a person’s chronological age. When biological age runs ahead, that gap is called epigenetic age acceleration, and it has been linked to a range of health conditions including cardiovascular disease, cognitive decline, and, more recently, depression.

The Horvath clock turned up nothing. No association with depression severity, no link to any symptom category. MonoDNAmAge was different. Monocyte age acceleration was significantly associated with the non-somatic dimension of depression: not with fatigue or disrupted sleep or physical agitation, but with anhedonia, with hopelessness, with a sense of personal failure. The statistical signal held across the full sample and, separately, within the HIV-positive subgroup.

“This is particularly interesting,” Perez says, “because people with HIV often have physical symptoms like fatigue that are attributed to their chronic illness rather than a depression diagnosis. But this flips that on its head because we found that these measures are associated with mood and cognitive symptoms, not somatic symptoms.” In other words, the very symptoms most likely to be missed, most likely to be chalked up to the disease itself rather than a treatable mood disorder, are the ones the monocyte clock appears most sensitive to.

Why Monocytes?

Monocytes are not bystanders in either HIV infection or depression. They are among the cells most heavily implicated in the chronic, low-grade inflammation that persists even in people with HIV who are virally suppressed on treatment. Elevated monocyte counts have been observed in people with depression more broadly. There is, then, perhaps something fitting in the finding that a clock calibrated specifically to these cells picks up a signal that a more general aging measure cannot. The mechanism is not yet understood. It could be that monocytes age faster under the chronic inflammatory burden that also drives certain depressive symptoms. Or the direction of causality could run differently, or both processes could share a common upstream driver. “The dynamics of monocyte aging and depression,” the researchers note dryly in the abstract, “warrant further study.”

Perez is careful about what the findings mean right now. This is a cross-sectional study, meaning it captures a snapshot rather than tracking changes over time. It cannot tell us whether monocyte aging precedes depression, whether depression accelerates monocyte aging, or some third factor is driving both. The sample, while reasonably sized, is drawn from a specific population. Replication across other groups is needed before anyone starts talking about clinical implementation.

But the longer horizon is genuinely interesting. “I think about the adage, ‘What gets measured gets managed,'” Perez says. “An aspirational goal in mental health would be to combine subjective experience with objective biological testing.” A blood-based biomarker for depression would change the field in ways that are hard to fully imagine: earlier detection in populations who don’t present with textbook symptoms, better stratification of patients for clinical trials, perhaps eventually a way to predict which treatments are most likely to work for a given individual based on their biological profile rather than trial and error. Precision oncology has been transforming cancer care for two decades. Precision psychiatry has lagged far behind, partly because we have never had the objective markers to make it possible.

The monocyte clock will not, by itself, solve that problem. But it is perhaps the kind of finding that, years from now, researchers will point to as an early hint that the immune system was always whispering something about the mind, and that someone finally thought to listen to the right cells.

The research is published in The Journals of Gerontology, Series A: https://doi.org/10.1093/gerona/glag083

Frequently Asked Questions

What is an epigenetic clock and how does it measure biological aging?

An epigenetic clock is an algorithm that estimates biological age by analysing chemical modifications to DNA, specifically patterns of methylation, the attachment of small chemical tags that influence which genes are switched on or off. Different clocks are calibrated to different cell types or tissues. When biological age runs ahead of chronological age, that gap is called epigenetic age acceleration, and it has been linked to faster rates of disease and decline.

Why were monocytes the key signal rather than a more general aging measure?

The study tested two epigenetic clocks: a broad one integrating many cell types, and one calibrated specifically to monocytes. Only the monocyte clock was associated with depressive symptoms. Monocytes are heavily involved in the chronic inflammation seen in both HIV and depression, which may explain why a clock tuned to these specific cells picks up signals that a more general measure misses. The mechanism is still not understood and is a key target for future research.

Could this lead to a blood test for depression?

Not yet, and probably not soon. The study is cross-sectional, meaning it shows an association at one point in time but cannot establish whether monocyte aging causes depression, results from it, or shares a common driver. Replication in larger and more diverse populations is needed before any clinical application would be possible. But the findings do move the field closer to having objective biological markers that could one day complement the self-reported symptom questionnaires that currently underpin depression diagnosis.

Why do women with HIV experience such high rates of depression?

Several factors converge. Chronic HIV infection sustains elevated levels of inflammation even in people on effective antiretroviral therapy, and inflammation has long been implicated in depression. There are also significant psychosocial pressures: stigma, economic disadvantage, and the cumulative stress of managing a long-term illness all increase vulnerability. When depression does develop, it tends to reduce engagement with HIV care, which compounds health risks, making early detection especially important in this population.

What are somatic versus non-somatic symptoms of depression, and why does the distinction matter?

Somatic symptoms of depression are physical: fatigue, appetite changes, sleep disruption, psychomotor agitation or slowing. Non-somatic symptoms are cognitive and emotional: feelings of worthlessness, hopelessness, anhedonia (the inability to feel pleasure), and difficulty concentrating. The distinction matters clinically because somatic symptoms in people with chronic illnesses like HIV are often attributed to the underlying condition rather than depression, causing the mood disorder to go unrecognized. The fact that monocyte aging tracks specifically with non-somatic symptoms means it may be sensitive to precisely the presentations most at risk of being missed.